Dr Ana Slipicevic holds a PhD in cellular biology and health economics education from the Medical Faculty University of Oslo and the London School of Economics. She has 20 years of oncology experience in both academic and industrial settings. Her academic research at the Oslo University Hospital, and The Wistar Institute, Philadelphia, focused on solid tumour biology and novel therapies. She also held the position of principal investigator for in vivo pharmacology at Medivir AS and, more recently, translational research director at Oncopeptides AB, where she led translational research efforts and implemented research strategies across clinical trial pipeline. In March 2022, she joined One carbon Therapeutics as VP of R&D and CEO.
Speaking In
2:30 PM - 2:45 PM
Monday, June 5
